Alternative mechanisms for long-acting β2-adrenergic agonists in COPD

Malcolm Johnson, Stephen Rennard

Research output: Contribution to journalReview article

151 Citations (Scopus)

Abstract

β2-Adrenergic agonists are commonly used as bronchodilators to treat patients with COPD. In addition to prolonged bronchodilation, long-acting β2-agonists (LABAs) exert other effects that may be of clinical relevance. These include inhibition of airway smooth-muscle cell proliferation and inflammatory mediator release, as well as nonsmooth-muscle effects, such as stimulation of mucociliary transport, cytoprotection of the respiratory mucosa, and attenuation of neutrophil recruitment and activation. This review details the possible alternative mechanisms of action of the LABAs, salmeterol and formoterol, in COPD.

Original languageEnglish (US)
Pages (from-to)258-270
Number of pages13
JournalChest
Volume120
Issue number1
DOIs
StatePublished - Jul 2001

Fingerprint

Adrenergic Agonists
Chronic Obstructive Pulmonary Disease
Mucociliary Clearance
Respiratory Mucosa
Neutrophil Activation
Cytoprotection
Neutrophil Infiltration
Bronchodilator Agents
Smooth Muscle Myocytes
Cell Proliferation
Muscles
Salmeterol Xinafoate
Formoterol Fumarate

Keywords

  • COPD
  • Formoterol
  • Long-acting β-adrenergic agonists
  • Salmeterol

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Alternative mechanisms for long-acting β2-adrenergic agonists in COPD. / Johnson, Malcolm; Rennard, Stephen.

In: Chest, Vol. 120, No. 1, 07.2001, p. 258-270.

Research output: Contribution to journalReview article

Johnson, Malcolm ; Rennard, Stephen. / Alternative mechanisms for long-acting β2-adrenergic agonists in COPD. In: Chest. 2001 ; Vol. 120, No. 1. pp. 258-270.
@article{3fd41d198e984d43a037d6e4652c430e,
title = "Alternative mechanisms for long-acting β2-adrenergic agonists in COPD",
abstract = "β2-Adrenergic agonists are commonly used as bronchodilators to treat patients with COPD. In addition to prolonged bronchodilation, long-acting β2-agonists (LABAs) exert other effects that may be of clinical relevance. These include inhibition of airway smooth-muscle cell proliferation and inflammatory mediator release, as well as nonsmooth-muscle effects, such as stimulation of mucociliary transport, cytoprotection of the respiratory mucosa, and attenuation of neutrophil recruitment and activation. This review details the possible alternative mechanisms of action of the LABAs, salmeterol and formoterol, in COPD.",
keywords = "COPD, Formoterol, Long-acting β-adrenergic agonists, Salmeterol",
author = "Malcolm Johnson and Stephen Rennard",
year = "2001",
month = "7",
doi = "10.1378/chest.120.1.258",
language = "English (US)",
volume = "120",
pages = "258--270",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1",

}

TY - JOUR

T1 - Alternative mechanisms for long-acting β2-adrenergic agonists in COPD

AU - Johnson, Malcolm

AU - Rennard, Stephen

PY - 2001/7

Y1 - 2001/7

N2 - β2-Adrenergic agonists are commonly used as bronchodilators to treat patients with COPD. In addition to prolonged bronchodilation, long-acting β2-agonists (LABAs) exert other effects that may be of clinical relevance. These include inhibition of airway smooth-muscle cell proliferation and inflammatory mediator release, as well as nonsmooth-muscle effects, such as stimulation of mucociliary transport, cytoprotection of the respiratory mucosa, and attenuation of neutrophil recruitment and activation. This review details the possible alternative mechanisms of action of the LABAs, salmeterol and formoterol, in COPD.

AB - β2-Adrenergic agonists are commonly used as bronchodilators to treat patients with COPD. In addition to prolonged bronchodilation, long-acting β2-agonists (LABAs) exert other effects that may be of clinical relevance. These include inhibition of airway smooth-muscle cell proliferation and inflammatory mediator release, as well as nonsmooth-muscle effects, such as stimulation of mucociliary transport, cytoprotection of the respiratory mucosa, and attenuation of neutrophil recruitment and activation. This review details the possible alternative mechanisms of action of the LABAs, salmeterol and formoterol, in COPD.

KW - COPD

KW - Formoterol

KW - Long-acting β-adrenergic agonists

KW - Salmeterol

UR - http://www.scopus.com/inward/record.url?scp=0034890383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034890383&partnerID=8YFLogxK

U2 - 10.1378/chest.120.1.258

DO - 10.1378/chest.120.1.258

M3 - Review article

C2 - 11451847

AN - SCOPUS:0034890383

VL - 120

SP - 258

EP - 270

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -